# A Prospective Study to Investigate Safety and Tolerability of Shorter Infusion of Fabrazyme

> **NCT06019728** · PHASE4 · COMPLETED · sponsor: **Sanofi** · enrollment: 8 (actual)

## Conditions studied

- Fabry's Disease

## Interventions

- **DRUG:** AGALSIDASE BETA (GZ419828)
- **DRUG:** Acetaminophen
- **DRUG:** Diphenhydramine
- **DRUG:** Dexamethasone
- **DRUG:** Montelukast
- **DRUG:** Loratadine
- **DRUG:** Cetirizine
- **DRUG:** Fexofenadine

## Key facts

- **NCT ID:** NCT06019728
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-11-10
- **Primary completion:** 2024-10-25
- **Final completion:** 2024-10-25
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2025-10-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06019728

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06019728, "A Prospective Study to Investigate Safety and Tolerability of Shorter Infusion of Fabrazyme". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06019728. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*